Posts by Sandra Ansanay-Alex
The Origin of Astrocytes Revealed
A major discovery in neuroscience: a study from the Faculty of Medicine (FacMed) and the Synapsy Center at the University of Geneva uncovers that cortical astrocytes originate from two distinct progenitor cell types. Long considered a uniform support cell population, astrocytes are now recognized as diverse and essential players in brain function, involved in…
Read MoreNovochizol’s AgrINovo Partnership: Swiss-Indian Alliance for Agricultural Innovation
Indian company Aquagri, its partner, and Novochizol SA, a Valais-based startup, announced the launch of AgrINovo, a transformative collaborative project. AgrINovo aims to unlock the full potential of Novochizol technology to foster a healthier, more sustainable agriculture in India and worldwide. Novochizol™ is derived from chitosan, made from chitin, the second most abundant polysaccharide…
Read MoreFuture4Care
Apply before 26 September 2025 for the Future4care‘s Go-To-Market Programme This one-year acceleration programme is designed to help startups jumpstart strategy, refine positioning, gain deep understanding of market insights and regulations, and speed up entry into two of Europe’s largest healthcare ecosystems. What’s in it for startups: ✔️ Workshops, masterclasses and educational activities to…
Read MoreMedtech Innovation Summit
The Medtech Innovation Summit, organised by the British-Swiss Chamber of Commerce, is taking place on 18 September 2025 in Zürich Are you an early-stage MedTech startup looking to scale, secure funding, learn about the best tips and trick, and connect with strategic partners? The MedTech Innovation Summit is a high-impact networking and knowledge-sharing event…
Read MoreFuture of Health Grant Conference 2025
The Future of Health Grant Conference 2025, organised in collaboration with the Swiss InsurTech Hub, is taking place on 9 September 2025 in Zürich. The event will explore the rise—and the boundaries—of personalized health. In a world where AI, digital tools, and advanced diagnostics are reshaping medicine, this event opens a multidisciplinary dialogue —…
Read MoreSwiss Health Valley Biotechs Advance Drug Pipelines with Promising Clinical Milestones
Three innovative biotech companies based in Western Switzerland, Stalicla, Legacy Healthcare and iOnctura, have recently achieved significant progress in their therapeutic pipelines, reinforcing the region’s position as a hub for health innovation. STALICLA: Advancing Precision Medicine for Autism Geneva-based STALICLA has received the green light from the U.S. Food and Drug Administration (FDA) to initiate…
Read MoreAnna and André Livio Glauser Foundation
The scholarships are intended to support young doctors who have a medical or surgical research project or a specific training programme. The Foundation’s support is provided in addition to one or more established grant. The Anna & André Livio-Glauser Foundation was created in 2018, when its founders, Mrs Monique Livio and her husband, Honorary…
Read MoreRelief Therapeutics is preparing a reverse merger with NeuroX, the successor to MindMaze
The merger must take the form of an exchange of all NeuroX shares for newly issued shares in Relief. The transaction, which is expected to be finalised before the end of the year, would value the Geneva-based company at CHF 100 million and its future partner at CHF 1 billion. The Geneva-based pharmaceutical company…
Read MoreAzureCell Therapies and Myriad Optics Awarded by Gebert Rüf Stiftung Innobooster Programme
Two Swiss Health Valley projects, from EPFL and University of Geneva, got a CHF 150’000 Innobooster grant from Gebert Rüf Stiftung programme: AzureCell Therapies and Myriad Optics. AzureCell Therapies | Bilal Fares, University of Geneva Every 9 min, a new patient is diagnosed with Parkinson’s, a condition long considered incurable due to the irreversible loss…
Read MoreBreaking Through Cancer’s Soft Defense: A Revolutionary Swiss Approach
Swiss researchers from EPFL, University of Geneva, and HUG hospitals are pioneering a groundbreaking strategy to overcome immunotherapy resistance by targeting cancer cells’ physical properties rather than their biology. The project received a CHF 1,4 million grant from Foundation Leenaards. “Our approach targets the mechanical properties of cancer cells by making their membranes stiffer,…
Read More